Back to search

National and Kapodistrian University of Athens

Μελέτη προγνωστικών και προβλεπτικών παραγόντων στον προχωρημένο ή μεταστατικό καρκίνο του τραχήλου της μήτρας που αντιμετωπίζεται με χημειοθεραπεία

Abstract

dc:description

ABSTRACTBackground: Recognizing resistance or susceptibility to the current standard cisplatin and paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical cancer.Methods: Forty-five tissue samples from patients participating in a phase II trial of cisplatin and ifosfamide, with or without paclitaxel were collected for retrograde analysis. Immunohistochemistry and genotyping was performed totest ERCC1, III β-tubulin, COX-2, CD4, CD8 and ERCC1 (C8092A and N118 N) and MDR1 (C3435T and G2677 T) gene polymorphisms, as possible predictive and prognostic markers. Results were statistically analyzed and correlatedwith patient characteristics and outcomes.Results: Patients with higher levels of ERCC1 expression had shorter PFS and OS than patients with low ERCC1 expression (mPFS:5.1 vs 10.2 months, p = 0.027; mOS:10.5 vs. 21.4 months, p = 0.006). Patients with TT in the siteof ERCC1 N118 N and GT in the site of MDR1 G2677 T polymorphisms had significantly longer PFS (p = 0.006 and p = 0.027 respectively). ERCC1 expression and the ERCC1 N118 N polymorphism remained independent predictors of PFS. Interestingly, high III beta tubulin expression was associated with chemotherapy resistance and fewer responses [5/20 (25%)] compared to lower III β-tubulin expression [15/23 (65.2%)] (p = 0.008). Finally, ΙΙΙ β-tubulinlevels and chemotherapy regimen were independent predictors of response to treatment.Conclusions: ERCC1 expression proved to be a significant prognostic factor for survival in our metastatic or recurrent cervical cancer population treated with cisplatin based chemotherapy. ERCC1 N118 N and MDR1 G2677 T polymorphism also proved of prognostic significance for disease progression, while overexpression of III β-tubulin was positively correlated with chemotherapy resistance.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Sofia, Karageorgopoulou
  • Καραγεωργοπούλου, Σοφία

Subjects

dc:subject × 2

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/43003

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Sofia, Karageorgopoulou; Καραγεωργοπούλου, Σοφία. Μελέτη προγνωστικών και προβλεπτικών παραγόντων στον προχωρημένο ή μεταστατικό καρκίνο του τραχήλου της μήτρας που αντιμετωπίζεται με χημειοθεραπεία. National and Kapodistrian University of Athens, 2018. http://hdl.handle.net/10442/hedi/43003